These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18695674)

  • 21. Bcl-2 and CrmA have different effects on transformation, apoptosis and the stability of I kappa B-alpha in chicken spleen cells transformed by temperature-sensitive v-Rel oncoproteins.
    White DW; Gilmore TD
    Oncogene; 1996 Sep; 13(5):891-9. PubMed ID: 8806678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NF-kappa B p100 is one of the high-molecular-weight proteins complexed with the v-Rel oncoprotein in transformed chicken spleen cells.
    Sif S; Gilmore TD
    J Virol; 1993 Dec; 67(12):7612-7. PubMed ID: 8230480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conservation and expression of an alternative 3' exon of Runx2 encoding a novel proline-rich C-terminal domain.
    Terry A; Kilbey A; Vaillant F; Stewart M; Jenkins A; Cameron E; Neil JC
    Gene; 2004 Jul; 336(1):115-25. PubMed ID: 15225881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of the v-Rel oncoprotein with cellular transcription factor Sp1.
    Sif S; Gilmore TD
    J Virol; 1994 Nov; 68(11):7131-8. PubMed ID: 7933095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AP-1 factors play an important role in transformation induced by the v-rel oncogene.
    Kralova J; Liss AS; Bargmann W; Bose HR
    Mol Cell Biol; 1998 May; 18(5):2997-3009. PubMed ID: 9566919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. vRel is an inactive member of the Rel family of transcriptional activating proteins.
    Richardson PM; Gilmore TD
    J Virol; 1991 Jun; 65(6):3122-30. PubMed ID: 1903456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel.
    Gilmore TD; Cormier C; Jean-Jacques J; Gapuzan ME
    Oncogene; 2001 Oct; 20(48):7098-103. PubMed ID: 11704834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure and autoregulation of the c-rel promoter.
    Hannink M; Temin HM
    Oncogene; 1990 Dec; 5(12):1843-50. PubMed ID: 2284104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids.
    Kralova J; Schatzle JD; Bargmann W; Bose HR
    J Virol; 1994 Apr; 68(4):2073-83. PubMed ID: 8138992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP).
    Chang CH; Scott GK; Baldwin MA; Benz CC
    Oncogene; 1999 Jun; 18(25):3682-95. PubMed ID: 10391676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein.
    You M; Ku PT; Hrdlicková R; Bose HR
    Mol Cell Biol; 1997 Dec; 17(12):7328-41. PubMed ID: 9372964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes.
    Fan Y; Rayet B; Gélinas C
    Oncogene; 2004 Feb; 23(5):1030-42. PubMed ID: 14647412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of the v-Rel oncoprotein with NF-kappaB and IkappaB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-2 are functional in vitro and in vivo.
    White DW; Pitoc GA; Gilmore TD
    Mol Cell Biol; 1996 Mar; 16(3):1169-78. PubMed ID: 8622661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rel homology domain-containing transcription factors in the cnidarian Nematostella vectensis.
    Sullivan JC; Kalaitzidis D; Gilmore TD; Finnerty JR
    Dev Genes Evol; 2007 Jan; 217(1):63-72. PubMed ID: 17120026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation.
    Walker WH; Stein B; Ganchi PA; Hoffman JA; Kaufman PA; Ballard DW; Hannink M; Greene WC
    J Virol; 1992 Aug; 66(8):5018-29. PubMed ID: 1321284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of telomerase activation by v-Rel and its contribution to transformation.
    Hrdlicková R; Nehyba J; Liss AS; Bose HR
    J Virol; 2006 Jan; 80(1):281-95. PubMed ID: 16352553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
    Gilmore TD
    Oncogene; 1999 Nov; 18(49):6925-37. PubMed ID: 10602467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human C-terminally truncated ERα variants resulting from the use of alternative exons in the ligand-binding domain.
    Hattori Y; Ishii H; Munetomo A; Watanabe H; Morita A; Sakuma Y; Ozawa H
    Mol Cell Endocrinol; 2016 Apr; 425():111-22. PubMed ID: 26835991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The v-Rel oncoprotein blocks apoptosis and proteolysis of I kappa B-alpha in transformed chicken spleen cells.
    White DW; Roy A; Gilmore TD
    Oncogene; 1995 Mar; 10(5):857-68. PubMed ID: 7898928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
    Mosialos G; Gilmore TD
    Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.